Abstract
Conventional periodontal therapy consists of mechanical scaling and root planing, and surgical treatment. This is still the mainstay of periodontal treatment. Adjunctive antimicrobial treatments, both systemic and local delivery, are becoming more sophisticated and useful in the treatment of recurrent periodontitis. Also very promising are adjunctive treatments that modulate the host response and decrease levels of destructive pro-inflammatory cytokines or matrix metalloproteinases. Smoking is a major risk factor for periodontitis and has a profound impact on the progression of periodontal bone and attachment loss. In the interest of improved periodontal health patients should be encouraged to stop smoking. Finally bacterial endotoxins that stimulate the release of pro-inflammatory cytokines can have systemic effects and may lead to pre-term, low birthweight babies, and cardiovascular diseases such as atherosclerosis, myocardial infarction and stroke. Health professionals need to be cognisant of the effect dental health can have on systemic diseases and refer for treatment when appropriate to ensure that optimum oral and systemic health is achieved for their patients.
Similar content being viewed by others
References
Greenwell H, Stovsky DA, Bissada NF. Periodontics in general practice: perspectives on nonsurgical therapy. J Am Dent Assoc 1987; 115(4): 591–5
Greenwell H, Bissada N, Stovsky D. Periodontics in general practice: perspectives on surgical therapy. Gen Dent 1989; 37(3): 228–33
Greenwell H, Bissada NF, Wittwer JW. Periodontics in general practice: professional plaque control. J Am Dent Assoc 1990; 121(5): 642–6
Jones CG. Chlorhexidine: is it still the gold standard? Periodontol 2000 1997; 15: 55–62
Mandel ID. Chemotherapeutic agents for controlling plaque and gingivitis. J Clin Periodontol 1988; 15(8): 488–98
Fine DH, Letizia J, Mandel ID. The effect of rinsing with Listerine antiseptic on the properties of developing plaque. J Clin Periodontol 1985; 12(8): 660–6
Goodson JM. Antimicrobial agents: response to a state of the science review. In: Loe H, Kleinman DV, editors. Dental plaque control measures and oral hygiene practices: proceedings from a state of the science workshop. Oxford: IRL Press, 1986: 143–6
Jackson RJ. Metal salts, essential oils and phenols: old or new? Periodontol 2000 1997; 15: 63–73
Greenwell H, Bissada NF, Dodge JR. Disease masking: a hazard of nonsurgical periodontal therapy. Periodontal Insights 1998; 5(4): 14–9
Greenstein G, Tonetti M. The role of controlled drug delivery for periodontitis. Position paper: American Academy of Periodontology. J Periodontol 2000; 71(1): 125–40
Reinhart R, Hart T, Dean JW, et al. Nine month clinical results of a locally delivered minocycline periodontal therapeutic system [abstract no. 26]. J Clin Periodontol 2000; 27 Suppl. 1: 24
Slots J. Systemic antibiotics in periodontics. Position paper: American Academy of Periodontology. J Periodontol 1996; 67(8): 831–8
Matisko M, Bissada NF. Short-term sequential administration of amoxicillin/clavulanate potassium and doxycycline in the treatment of recurrent periodontitis. J Periodontol 1993; 64(6): 553–8
Gemmell E, Marshall RI, Seymour GJ. Cytokines and prostaglandins in immune homeostasis and tissue destruction in periodontal disease. Periodontol 2000 1997; 14: 112–43
Reynolds JJ, Meikle MC. Mechanisms of connective tissue matrix destruction in periodontitis. Periodontol 2000 1997; 14: 144–57
Jeffcoat MK, Lewis CE, Reddy MS, et al. Post-menopausal bone loss and its relationship to oral bone loss. Periodontol 2000; 23: 94–102
Ng VW, Bissada NF. Clinical evaluation of systemic doxycycline and ibuprofen administration as adjunctive treatment for adult periodontitis. J. Periodontol 1998; 69(7): 772–6
Golub LM, McNamara TF, Ryan ME, et al. Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J Clin Periodontol 2001; 28(2): 146–56
Paquette DW, Williams RC. Modulation of host inflammatory mediators as a treatment strategy for periodontal diseases. Periodontol 2000; 24: 239–52
Williams RC, Offenbacher S, Jeffcoat MK, et al. Indomethacin or flurbiprofen treatment of periodontitis in beagles: effect on crevicular fluid arachidonic acid metabolites compared with effect on alveolar bone loss. J Periodontal Res 1988; 23(2): 134–8
Bodnar T, Bissada N, DeLuca D, et al. Clinical effects and TNF-α levels following the local delivery of NSAIDS and antibiotics for the treatment of adult periodontitis [abstract]. J Dent Res 1998; 77(51): 722
Williams RC, Jeffcoat MK, Howell TH, et al. Topical flurbiprofen treatment of periodontitis in beagles. J Periodont Res 1988; 23(3): 166–9
Paquette DW, Fiorellini JP, Martuscelli H, et al. Enantio-specific inhibition of ligature-induced periodontitis in beagles with topical (S)-ketoprofen. J Clin Periodontol 1997; 24(8): 521–8
Nakaya H, Osawa G, Iwasaki N, et al. Effects of bisphosphonate on matrix metalloproteinase enzymes in human periodontal ligament cells. J Periodontol 2000; 71(7): 1158–66
Jeffcoat MK, Reddy MS. Alveolar bone loss and osteoporosis: evidence for a common mode of therapy using the bisphosphonate alendronate. In: Davidovitch Z, editor. The biologic mechanism of tooth resorption and replacement by implants. Boston (MA): Harvard Society for the Advancement of Orthodontics, 1966: 365–73
Yaffe A, Golomb G, Breuer E, et al. The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model. J Periodontol 2000; 71(10): 1607–12
Gaffar A, Scherl D, Afflitto J, et al. The effect of triclosan on mediators of gingival inflammation. J Clin Periodontol 1995; 22(6): 480–4
Rosling B, Wannfors B, Volpe AR, et al. The use of a triclosan/copolymer dentifrice may retard the progression of periodontitis. J Clin Periodontol 1997; 24(12): 873–80
Johnson GK. Tobacco use and the periodontal patient. Position paper: American Academy of Periodontology. J Periodontol 1999; 70(11): 1419–27
MacFarlane GD, Herzberg MC, Wolff LF, et al. Refractory periodontitis associated with abnormal polymorphonuclear leukocyte phagocytosis and cigarette smoking. J Periodontol 1992; 63(11): 908–13
Scannapieco FA. Periodontal disease as a potential risk factor for systemic diseases. Position paper: American Academy of Periodontology. J Periodontol 1998; 69(7): 841–50
Offenbacher S, Katz V, Fertik G, et al. Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol 1996; 67(10): 1103–13
Bazile A, Bissada N, Nair R, et al. Periodontal assessment of patients undergoing angioplasty for the treatment of coronary artery disease. J Periodontol 2002; 73(6): 631–6
Beck J, Garcia R, Heiss G, et al. Periodontal disease and cardiovascular disease. J Periodontol 1996; 67(10): 1123–37
Kweider M, Lowe GD, Murray GD, et al. Dental disease, fibrinogen and white cell count; links with myocardial infarction? Scott Med J 1993; 38(3): 73–4
Herzberg M, MacFarlane GD, Gong K, et al. The platelet inactivity phenotype of Streptococcus sanguis influences the course of experimental endocarditis. Infect Immun 1992; 60(11): 4809–18
Herzberg MC, Meyer MW. Effects of oral flora on platelets: possible consequences in cardiovascular disease. J Periodontol 1996; 67 (10 Suppl.): 1138–42
Acknowledgements
No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greenwell, H., Bissada, N.F. Emerging Concepts in Periodontal Therapy. Drugs 62, 2581–2587 (2002). https://doi.org/10.2165/00003495-200262180-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200262180-00002